These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30688316)

  • 1. Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy.
    Nagy S; Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Bieri O; Vuillerot C; Bonati U; Fischer D
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30688316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis.
    Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Schroeder J; Naduvilekoot Devasia A; Zuesli S; Bernert G; Laugel V; Bloetzer C; Steinlin M; Capone A; Gloor M; Tobler P; Haas T; Bieri O; Zumbrunn T; Fischer D; Bonati U
    Neuromuscul Disord; 2018 Jan; 28(1):16-23. PubMed ID: 29174526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Hafner P; Bonati U; Klein A; Rubino D; Gocheva V; Schmidt S; Schroeder J; Bernert G; Laugel V; Steinlin M; Capone A; Gloor M; Bieri O; Hemkens LG; Speich B; Zumbrunn T; Gueven N; Fischer D
    JAMA Netw Open; 2019 Oct; 2(10):e1914171. PubMed ID: 31664444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study.
    Fischer D; Hafner P; Rubino D; Schmid M; Neuhaus C; Jung H; Bieri O; Haas T; Gloor M; Fischmann A; Bonati U
    Neuromuscul Disord; 2016 Jul; 26(7):414-22. PubMed ID: 27209345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy.
    Silva EC; Machado DL; Resende MB; Silva RF; Zanoteli E; Reed UC
    Arq Neuropsiquiatr; 2012 Mar; 70(3):191-5. PubMed ID: 22392111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy.
    Nagy S; Schädelin S; Hafner P; Bonati U; Scherrer D; Ebi S; Schmidt S; Orsini AL; Bieri O; Fischer D
    Muscle Nerve; 2020 Jan; 61(1):63-68. PubMed ID: 31469921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association Between Physical Activity/Heart Rate Variability Data Obtained Using a Wearable Device and Timed Motor Functional Tests in Patients with Duchenne Muscular Dystrophy: A Pilot Study.
    Nakamura A; Matsumura T; Takeshima Y; Kuru S; Imazaki M; Nonomura H; Kaiya H
    J Neuromuscul Dis; 2024; 11(3):715-724. PubMed ID: 38607760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials.
    Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP
    Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy.
    Kempen JC; Harlaar J; van der Kooi AJ; de Groot IJ; van den Bergen JC; Niks EH; Verschuuren JJ; Brehm MA
    Neuromuscul Disord; 2014 Mar; 24(3):216-21. PubMed ID: 24365209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timed rolling and rising tests in Duchenne muscular dystrophy ambulant boys: a feasibility study.
    Sobierajska-Rek A; Jabłońska-Brudło J; Dąbrowska A; Wojnicz W; Meyer-Szary J; Wierzba J
    Minerva Pediatr (Torino); 2024 Apr; 76(2):208-216. PubMed ID: 38639735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI Assessment of Motor Capabilities in Patients with Duchenne Muscular Dystrophy According to the Motor Function Measure Scale.
    Suslov V; Suslova G; Lytaev S
    Tomography; 2022 Apr; 8(2):948-960. PubMed ID: 35448710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boys With Duchenne Muscular Dystrophy: 1-Year Locomotor Changes in Relation to a Control Group.
    Martini J; Caromano FA; Carvalho EV; Goya PA; Hayasaka RM; Nakazune S; Fávero FM; Voos MC
    Percept Mot Skills; 2018 Feb; 125(1):40-56. PubMed ID: 29171337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.